Intensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients

• The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
  
  
  
   
• Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients
  
  
  
   
• Seven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple Negative Breast Cancer ("TNBC"), and several patients have been treated

SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.